Seminars in Oncology
Volume 31, Issue 1 , Pages 4-21 , February 2004

Nonmyeloablative stem cell transplantation: reduced-intensity conditioning for cancer immunotherapy—from bench to patient bedside

  • Shimon Slavin

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
    • Corresponding Author InformationAddress reprint requests to Shimon Slavin, MD, Professor and Chairman, Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem 91120, Israel
    • ,
  • Shoshana Morecki

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Lola Weiss

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Michael Y Shapira

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Igor Resnick

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel
    • ,
  • Reuven Or

      Affiliations

    • Department of Bone Marrow Transplantation and Cancer Immunotherapy, Danny Cunniff Leukemia Research Laboratory, Hadassah University Hospital, Jerusalem, Israel

References 

  1. Sinkovics JG, Shullenberger CC, Howe CD. Prolongation and prevention of Rauscher virus mouse leukemia by spleen cells of naturally resistant or actively immunized mice. Clin Res. 1965;13:36–39
  2. Boranic M, Tonkovic I. Time pattern of the antileukemia effect of graft-versus-host reaction in mice, I. Cellular events. Cancer Res. 1971;31:1140–1147
  3. Weiden PL, Sullivan KM, Fluornoy N, et al.  Antileukemic effect of chronic graft-versus-host disease (Contribution to improved survival after allogeneic marrow transplantation). N Engl J Med. 1981;304:1529–1533
  4. Weiden PL, Fluornoy N, Sanders JE, et al.  Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. Transplantation. 1981;13:248–251
  5. Bortin MM, Truitt RL, Rimm AA, et al.  Graft-versus-leukaemia reactivity induced by alloimmunization without augmentation of graft-versus-host reactivity. Nature. 1979;281:490–491
  6. Slavin S, Weiss L, Morecki S, et al.  Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155–161
  7. Truitt RL, Shih F-H, LeFever AV, et al.  Characterization of alloimmunization-induced T lymphocytes reactivated against AKR leukemia in vitro and correlation with graft-vs-leukemia activity in vivo. J Immunol. 1983;131:2050–2058
  8. Meredith RF, O’Kunewick JP. Possibility of graft-vs-leukemia determinants independent of the major histocompatibility complex in allogeneic marrow transplantation. Transplantation. 1983;35:378–385
  9. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997–1000
  10. Slavin S, Strober S. Spontaneous murine B-cell leukemia. Nature. 1978;272:624–626
  11. Slavin S, Weiss L, Morecki S, et al.  Ultrastructural, cell membrane and cytogenetic characteristics of B-cell leukemia (BCL1), a murine model of chronic lymphocytic leukemia. Cancer Res. 1981;41:4162–4166
  12. Vourka-Karussis U, Karussis D, Ackerstein A, et al.  Enhancement of graft versus leukemia effect (GVL) with recombinant human interleukin 2 (rIL-2) following bone marrow transplantation in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol. 1995;23:196–201
  13. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB x NZW)F1 hybrids with spontaneous lymphosarcoma. J Immunol. 1984;132:997–1000
  14. Morecki S, Moshel Y, Gelfend Y, et al.  Induction of graft vs tumor effect in a murine model of mammary adenocarcinoma. Int J Cancer. 1997;71:59–63
  15. Morecki S, Yacovlev E, Diab A, et al.  Allogeneic cell therapy for a murine mammary carcinoma. Cancer Res. 1998;58:3891–3895
  16. Morecki S, Yacovlev E, Gelfand Y, et al.  Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother. 2001;24:114–121
  17. Prigozhina T, Gurevitch O, Morecki S, et al.  Non-myeloablative allogeneic bone marrow transplantation as immunotherapy for hematologic malignancies and metastatic solid tumors in pre-clinical models. Exp Hematol. 2002;30:89–96
  18. Slavin S, Weiss L, Morecki S, et al.  Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI). Cancer Immunol Immunother. 1981;11:155–158
  19. Slavin S, Fuks Z, Kaplan HS, et al.  Transplantation of allogeneic bone marrow without graft vs host disease using total lymphoid irradiation. J Exp Med. 1978;147:963–972
  20. Weiss L, Reich S, Slavin S. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders. I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL2-activated cell-mediated immunotherapy. Cancer Invest. 1992;10:19–26
  21. Weiss L, Reich S, Slavin S. Effect of cyclosporine A and methylprednisolone on the GVL effect across major histocompatibility barriers in mice following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1990;6:229–233
  22. Weiss L, Reich S, Slavin S. The role of antibodies to IL-2 receptor and anti-Asialo GMI antibodies on GVL effects induced by BMT in murine B cell leukemia. Bone Marrow Transplant. 1995;16:457–461
  23. Weiss L, Reich S, Slavin S. Alloimmune-mediated GVL effects induced by unmodified and in vitro r-IL2 activated bone marrow and lymphocytes from different lymphoid compartments. Cytokines Cell Mol Ther. 1999;5:145–152
  24. Slavin S, Ackerstein A, Kedar E, et al.  Induction of cell-mediated IL2-activated antitumor responses in conjunction with autologous and allogeneic bone marrow transplantation. Transplant Proc. 1991;23:802–803
  25. Ji YH, Weiss L, Zeira M, et al.  Allogeneic cell-mediated immunotherapy of leukemia with immune donor lymphocytes to up-regulate anti-tumor effects and down-regulate anti-host responses. Bone Marrow Transplant. 2003;32:495–504
  26. Morecki S, Yacovlev E, Gelfand Y, et al.  Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother. 2001;24:114–121
  27. Slavin S, Ackerstein A, Weiss L. Adoptive immunotherapy in conjunction with bone marrow transplantation—Amplification of natural host defence mechanisms against cancer by recombinant IL2. Nat Immun Cell Growth Regul. 1988;7:180–184
  28. Morecki S, Slavin S. Tumor dormancy induced by immune effector mechanisms in a murine model of B cell leukemia/lymphoma (BCL1). In:  Yafenof E,  Scheuermann RH editor. Premalignancy and Tumor Dormancy. New York, NY: Thomas; 1996;p. 137–146
  29. Sullivan KM, Weiden PL, Storb R, et al.  Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–1726
  30. Ringden O, Horowitz MM. Graft-vs-leukemia reactions in humans. Transplant Proc. 1989;21:2989–2992
  31. Horowitz M, Gale RP, Sondel PM, et al.  Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–562
  32. Eibl B, Schwaighofer H, Nachbaur D, et al.  Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88:1501–1508
  33. Ben-Yosef R, Or R, Nagler A, et al.  Graft vs tumor and graft vs leukemia in patient with concurrent breast cancer and acute myelocytic leukemia. Lancet. 1996;348:1242–1243
  34. Ueno NT, Rondón G, Mirza NQ, et al.  Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16:986–993
  35. Or R, Ackerstein A, Nagler A, et al.  Allogeneic cell mediated immunotherapy for breast cancer after autologous stem cell transplantation (A clinical pilot study). Cytokines Cell Mol Ther. 1998;4:1–6
  36. Childs RW, Clave E, Tisdale J, et al.  Successful treatment of metastatic renal cell carcinoma with a non-myeloablative allogeneic peripheral-blood progenitor-cell transplant (Evidence for a graft-versus-tumor effect). J Clin Oncol. 1999;17:2044–2050
  37. Childs R, Chernoff A, Contentin N, et al.  Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;11:750–758
  38. Kapelushnik J, Or R, Aker M, et al.  Allogeneic cell therapy of severe beta thalassemia major by displacement of host stem cells in mixed chimera by donor blood lymphocytes. Bone Marrow Transplant. 1996;19:96–98
  39. Aker M, Kapelushnik J, Pugatsch T, et al.  Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic BMT for beta thalassemia major. J Pediatr Hematol Oncol. 1998;20:145–148
  40. Slavin S, Nagler A, Naparstek E, et al.  Minitransplants and cell-based therapies for malignant and non-malignant disorders. Curr Opin Organ Transplant. 1999;4:184–188
  41. Kolb HJ, Schattenberg A, Goldman JM, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients (European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia). Blood. 1995;86:2041–2050
  42. Slavin S, Nagler A, Varadi G, et al.  Graft vs autoimmune lymphocytes (GVA) following allogeneic bone marrow transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853–857
  43. Slavin S, Nagler A, Varadi G, et al.  Graft vs autoimmune lymphocytes (GVA) following allogeneic bone marrow transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853–857
  44. Slavin S, Or R, Naparstek E, et al.  Cellular-mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in experimental animals and man. Blood. 1988;72:407a; (suppl 1, abstr)
  45. Slavin S, Naparstek E, Or R, et al.  Prevention of GVHD and induction of graft vs leukemia (GVL) effects (Will it ever be possible?). Bone Marrow Transplant. 1998;3(suppl 1):208–209
  46. Slavin S, Ackerstein A, Nagler A, et al.  Cell-mediated cytokine-activated immunotherapy (CCI) of malignant hematological disorders for eradication of minimal residual disease (MRD) in conjunction with conventional chemotherapy or bone marrow transplantation (BMT). Blood. 1990;76:566a; (suppl 1, abstr)
  47. Slavin S, Naparstek E, Nagler A, et al.  Allogeneic cell therapy for relapsed leukemia following bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol. 1995;23:1553–1562
  48. Slavin S, Naparstek E, Nagler A, et al.  Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse post allogeneic bone marrow transplantation. Blood. 1996;87:2195–2204
  49. Naparstek E, Or R, Nagler A, et al.  T-cell-depleted allogeneic bone marrow transplantation for acute leukaemia using Campath-1 antibodies and post-transplant administration of donor’s peripheral blood lymphocytes for prevention of relapse. Br J Haematol. 1995;89:506–515
  50. Naparstek E, Nagler A, Or R, et al.  Allogeneic cell mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic BMT for hematological malignancies. In:  Cecka JM,  Teraskaki PI editor. Clinical Transplants. Los Angeles, CA: UCLA Tissue Typing Laboratory; 1996;p. 281–290
  51. Bacigalupo A, Van Lint MT, Occhini D, et al.  Increased risk of leukemia relapse with high dose cyclosporine A after allogeneic marrow transplantation for acute leukemia. Blood. 1991;77:1423–1428
  52. Slavin S, Or R, Kapelushnik Y, Drakos P, et al.  Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia. 1992;6:164–166
  53. Kolb HJ, Mittermueller J, Clemm CH, et al.  Donor leukocyte transfusion for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–2465
  54. Goldman JM, Gale RP, Horowitz MM, et al.  Bone marrow transplantation for chronic myelogenous leukemia in chronic phase (Increased risk for relapse associated with T-cell depletion). Ann Intern Med. 1988;108:806–814
  55. Bar BM, Schattenberg A, Mensink EJ, et al.  Donor leukocyte infusions for chronic myeloid leukemia relapsed after allogeneic bone marrow transplantation. J Clin Oncol. 1993;11:513–519
  56. Leber B, Walker IR, Rodrigues A, et al.  Reinduction of remission of chronic myeloid leukemia by donor leukocyte transfusion following relapse after bone marrow transplantation (Recovery complicated by initial pancytopenia and late dermatomyositis). Bone Marrow Transplant. 1993;12:405–407
  57. Drobyski WR, Keever CA, Roth MS, et al.  Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation (Efficacy and toxicity of a defined T-cell dose). Blood. 1993;82:2310–2318
  58. Porter DL, Roth MS, McGarigle C, et al.  Induction of graft versus host disease for relapsed chronic myeloid leukemia. N Eng J Med. 1994;330:100–106
  59. Mackinnon S, Papadopoulos EB, Carabassi MH, et al.  Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation (Separation of graft-versus-leukemia responses from graft-versus-host disease). Blood. 1995;86:1261–1268
  60. Papadopoulos EB, Ladanyi M, Emanual D, et al.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lympho-proliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185–1191
  61. Kolb H, Schattenberg A, Goldman J, et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86:2041–2050
  62. Collins RH, Shpilberg O, Drobyski WR, et al.  Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997;15:433–444
  63. Kuzushima K, Yamamoto M, Kimura H, et al.  Establishment of anti-Epstein-Barr virus (EBV) cellular immunity by adoptive transfer of virus specific cytotoxic T lymphocytes from an HLA matched sibling to a patient with severe chronic active EBV infection. Clin Exp Immunol. 1996;103:192–198
  64. Gubbay I, Collignon J, Koopman P, et al.  A gene mapping to the sex-determining region of the mouse y chromosome is a member of a novel family of embryologically expressed genes. Nature. 1990;346:245–250
  65. Pugatsch T, Oppenheim A, Slavin S. Improved single-step PCR assay for sex identification post-allogeneic sex-mismatched BMT. Bone Marrow Transplant. 1996;17:273–275
  66. Raanani P, Dazzi F, Sohal J, et al.  The rate and kinetics of molecular response to donor leucocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol. 1997;99:945–950
  67. Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant. 1993;11:329–336
  68. Kolb HJ, Mittermuller J, Gunther W, et al.  Adoptive immunotherapy in human and canine chimeras. Bone Marrow Transplant. 1993;12:561–564
  69. Keating MJ, O’Brien S, McLaughlin P, et al.  Clinical experience with fludarabine in hemato-oncology. Hematol Cell Ther. 1996;38(suppl 2a):S83–S91
  70. Keating MJ, O’Brien S, Lerner S, et al.  Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92:1165–1171
  71. Slavin S, Nagler A, Naparstek E, et al.  Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non malignant hematologic diseases. Blood. 1998;91:756–763
  72. Khouri IF, Keating M, Korbling M, et al.  Transplant-lite (Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies). J Clin Oncol. 1998;16:2817–2824
  73. Giralt S, Cohen A, Mehra R, et al.  Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenitor cell transplantation in poor candidates for conventional myeloablative conditioning. Blood. 1997;90:1853a; (suppl 1, abstr)
  74. McSweeney PA, Wagner JL, Maloney DG, et al.  Outpatient PBSC allografts using immunosuppression with low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant. Blood. 1998;92:519a; (suppl 1, abstr 2133)
  75. Carella AM, Giralt S, Slavin S. Low intensity regimens with allogeneic hematopoietic stem cell transplantation as treatment of hematologic neoplasia. Haematologica. 2000;85:304–313
  76. Carella AM, Champlin R, Slavin S, et al.  “Mini-allografts” (Ongoing trials in humans). Bone Marrow Transplant. 2000;25:345–350
  77. Kapelushnik J, Aker M, Pugatsch T, et al.  Bone marrow transplatation from a cadaveric donor. Bone Marrow Transplant. 1998;21:857–858
  78. Nagler A, Ackerstein A, Kapelushnik J, et al.  Donor lymphocyte infusion post non-myeloablative allogeneic peripheral blood stem cell transplantation for chronic granulomatous disease. Bone Marrow Transplant. 1999;24:339–342
  79. Kapelushnik J, Or R, Slavin S, et al.  Fludarabine based protocol for BMT in Fanconi anemia. Bone Marrow Transplant. 1997;29:1109–1110
  80. Aker A, Varadi G, Slavin S, et al.  Fludarabine-based protocol for human umbilical cord blood transplantation in children with Fanconi’s anemia. J Pediatr Hematol Oncol. 1999;21:237–239
  81. Nagler A, Slavin S, Varadi G, et al.  Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for a malignant lymphoma. Bone Marrow Transplant. 2000;25:1021–1028
  82. Slavin S, Nagler A, Varadi G, et al.  Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853–857
  83. Slavin S. Treatment of myeloid leukemias with non-myeloablative stem cell transplantation: Accomplishments and future goals. Educational Symposium, ASH, December 2000. Hematology. 2000;1:81–89
  84. Nagler A, Aker M, Or R, et al.  Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362–370
  85. Giralt S, Gajewski J, Khouri I, et al.  Induction of graft-versus-leukemia as primary treatment of chronic myelogenous leukemia. Blood. 1997;90:1857a; (suppl 1, abstr)
  86. Giralt S, Hester J, Huh Y, et al.  CD8-depleted donor lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood. 1995;86:4337–4343
  87. Giralt S, Cohen A, Mehra R, et al.  Preliminary results of fludarabine/melphalan or 2CDA/melphalan as preparative regimens for allogeneic progenito cell transplantation in poor candidates for conventional myeloablative conditioning. Blood. 1997;90:1853a; (suppl 1, abstr)
  88. Carella AM, Lerma E, Dejana A, et al.  Engraftment of HLA-matched sibling hematopoietic stem cells after immunosuppressive conditioning regimen in patients with hematologic neoplasias. Haematologica. 1998;83:904–909
  89. Carella AM, Lerma E, Corsetti MT, et al.  Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. Br J Haematol. 1998;103:565–567
  90. Yu C, Storb R, Mathey B, et al.  DLA-identical bone marrow grafts after low-dose total body irradiation (Effects of high-dose corticosteroids and cyclosporine on engraftment). Blood. 1995;86:4376–4381
  91. Storb R, Yu C, Wagner JL, et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048–3054
  92. Storb R, Yu C, Barnett T, et al.  Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given lymph node irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1999;90:1131–1136
  93. Pelot MR, Pearson DA, Swenson K, et al.  Lymphohematopoietic graft-vs-host reactions can be induced without graft-vs-host disease in murine mixed chimeras established with a cyclophosphamide-based non-myeloablative conditioning regimen. Biol Blood Marrow Transplant. 1999;5:133–143
  94. Sykes M, Preffer F, McAfee S, et al.  Mixed lymphohematopoietic chimerism and graft-vs-lymphoma effects are achievable in adult recipients following non-myeloablative therapy and HLA-mismatched donor bone marrow transplantation. Lancet. 1999;353:1755–1759
  95. Morecki S, Yacovlev E, Gelfand Y, et al.  Cell therapy with pre-immunized effector cells mismatched for minor histocompatible antigens, in the treatment of a murine mammary carcinoma. J Immunother. 2001;24:114–121

PII: S0093-7754(03)00559-1

doi: 10.1053/j.seminoncol.2003.10.016

Seminars in Oncology
Volume 31, Issue 1 , Pages 4-21 , February 2004

Article Tools

* Image Usage & Resolution